<SEC-DOCUMENT>0001104659-24-005204.txt : 20240119
<SEC-HEADER>0001104659-24-005204.hdr.sgml : 20240119
<ACCEPTANCE-DATETIME>20240119160544
ACCESSION NUMBER:		0001104659-24-005204
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20240119
DATE AS OF CHANGE:		20240119

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Precipio, Inc.
		CENTRAL INDEX KEY:			0001043961
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				911789357
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-271277
		FILM NUMBER:		24545611

	BUSINESS ADDRESS:	
		STREET 1:		12325 EMMET ST
		CITY:			OMAHA
		STATE:			NE
		ZIP:			68164
		BUSINESS PHONE:		203 787 7888

	MAIL ADDRESS:	
		STREET 1:		4 SCIENCE PARK
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TRANSGENOMIC INC
		DATE OF NAME CHANGE:	20000119
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>tm243323d1_424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Filed Pursuant to Rule 424(b)(5) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-271277</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS SUPPLEMENT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(To prospectus dated on April 25, 2023) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm243323d1_424b5img01.jpg" ALT="" STYLE="height: 66px; width: 304px"></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Up to $865,889 of</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock </B></P>



<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus supplement amends and supplements the information in
the prospectus supplement, dated April 25, 2023 (the &ldquo;Prior Prospectus Supplement&rdquo;), filed with the Securities and Exchange
Commission as a part of our registration statement on Form S-3 (File No. 333-271277), as amended, relating to the offer and sale of up
to $5,800,000 of shares of our common stock, $0.01 par value per share, pursuant to the Sales Agreement (the &ldquo;Sales Agreement&rdquo;)
we previously entered into with A.G.P./Alliance Global Partners (the &ldquo;Sales Agent&rdquo;). This prospectus supplement is registering
the offer and sales of up to $865,889 of shares of our common stock. This prospectus supplement should be read in conjunction with
the Prior Prospectus Supplement, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes
the information contained in the Prior Prospectus Supplement. This prospectus supplement is not complete without, and may only be delivered
or utilized in connection with, the Prior Prospectus Supplement and any future amendments or supplements thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are subject to General Instruction I.B.6 of Form S-3, which limits
the amounts that we may sell under the registration statement of which this prospectus supplement and the Prior Prospectus Supplement
are a part. After giving effect to these limitations and the current public float of our common stock, and after giving effect to the
terms of the Sales Agreement, we currently may offer and sell shares of our common stock having an aggregate offering price of up to $865,889
under the Sales Agreement. If our public float increases such that we may sell additional amounts under the Sales Agreement and the registration
statement of which this prospectus supplement and the Prior Prospectus Supplement are a part, we will file another prospectus supplement
prior to making additional sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is listed on The Nasdaq Capital Market under the symbol
 &ldquo;PRPO&rdquo;. The aggregate market value of our common stock held by non-affiliates as of January 17, 2024 pursuant to General
Instruction I.B.6 of Form S-3 is $9,718,012, which was calculated based on 1,362,975 shares of our common stock outstanding held
by non-affiliates and at a price of $7.13 per share, the closing price of our common stock on November 20, 2023. As of the date hereof,
we have offered and sold $2,373,447.40 of securities pursuant to General Instruction I.B.6 of Form S-3 during the prior 12 calendar month
period that ends on and includes the date hereof, including $373,447.15 of securities in accordance with the Sales Agreement under the Prior
Prospectus Supplement and $2,000,000 of securities pursuant to a separate public primary offering. As a result of the limitations of
General Instruction I.B.6 of Form S-3, and in accordance with the terms of the Sales Agreement, we are registering the offer and sale
of shares of our common stock having an aggregate offering price of up to $865,889 from time to time through the Sales Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investing in our securities involves a high degree of risk. You
should review carefully the risks and uncertainties described under the section titled &ldquo;Risk Factors&rdquo; on page 36 of the Prior
Prospectus Supplement and in our most recent Quarterly Report on Form 10-Q, and any amendments thereto, which are incorporated by reference
into the Prior Prospectus Supplement, and under similar headings in the other documents that are filed after the date hereof and incorporated
by reference into this prospectus supplement and the Prior Prospectus Supplement for a discussion of the factors you should consider before
making a decision to invest in our common stock. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or determined if this prospectus or the Prior Prospectus Supplement is truthful
or complete. Any representation to the contrary is a criminal offense. </B></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 14pt"><B>A.G.P.</B></FONT> </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus is January 19, 2024. </B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm243323d1_424b5img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm243323d1_424b5img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !" 3 # 2(  A$! Q$!_\0
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MH 6BBDH 6BDS1F@!:*:3BE!H 6BDS1F@!:*2B@!:*;FEH 6BDS1F@!:*2EH
MXO4_ OG.\MC<,'8DE)><GZURU_HU_II(NK9U7^^!E?SKUH<4C(KJ58 J>H(K
MGGAXRU1R5,)">JT/)=+U6XTF[$]NW^\AZ,/>O0[:YTWQ7I926-9(SCS(FZJ:
MCU'PAIM]EUC,$I_CCX'Y5SY\-ZQH-U]JTUQ<*O4+P6'H14052D^Z(IQJT'9Z
MHZV'0-*ACVQZ?;;?>,&F2^'-*>"2+[#"$DY;:N#GU![4[2-8CU.'!5HKA/\
M60N,,I_PK2S76IMJ]SL5I(\QUS1+KPM?1W=G*WD[ODD[J?0UW/A[64UK35G
M"R*=LB^C54\9WUO8Z%)]JMWF28^6 IQM/8UYKIVN7>F3 VLK1QLZF0 _> />
MNF,'5A?J8I>SGIL>U#FLW6]&36K9(7N;FW"MNW6[[2?8^U:$3B2-'7HR@BG5
MS;'0<E_PKZW_ .@QJ_\ X$FD_P"%?6X_YC&K_P#@0:ZZD-/G?<#A;@ZMX'GB
MGEOIM1T9W"2B;F2'/0Y]*["\MDU/3Y(/-D1)E_UD3;6 ZY!KG_B%>Q)X=ET\
M8>ZOBL4,0ZDD]<>U=%I\+6VGV\#G+QQ*I/N!3>UP.:_X5]!_T&-7_P# DT?\
M*^M_^@QJ_P#X$FNNS12YV%CA[[0]9\,1-?Z-JES>11#=+:W3;MRCK@^M=/I^
MJ1:QH<=];DA)HBP]5..1^!I=<U&WTK2;BZNW5$5#@'^(XX K(\%VDUEX)A6=
M2CR*\NT]@V2*>ZNQ;'/>%/"D.O:(M]=ZAJ*RO(X(2<@<&MK_ (5U8_\ 02U3
M_P "34GPX_Y%&+_KM)_Z%754Y2=QG(_\*ZL?^@EJG_@2:NZ1X.MM&OUNX;V_
ME=01MEF+*<^U=#FBIYF R25(8FDD8*B#+,3@ >M<=_;6L^*YY(_#^++3D)5K
MZ1<M(?\ 8']:G\<RRWKZ=H4#E#J,V)6'41KR:Z:SLX;&UBMK= D42A54=A3V
M5Q'+CP )1NO-<U6:0]6$VT?E1_PKNU_Z"VK?^!!KL**7,QF=INF+I&E?98YY
MYE0,0\S[G_.L?X?RR7'A4--(\C&XE&YFR?O&NEE_U+_[I_E7+_#C_D5!_P!?
M,O\ Z$:?V6Q"/X!@>1G_ +7U<;B3@7)P*3_A7UO_ -!C5_\ P)-=;1^%+F:&
M<;-X*OK)#-HNNWZ7*\A+B3>C^QK5\*Z[)K=A(+J/RKVU<PW$?HP[CV-;4DJ0
MQM)*P1%&69C@ 5R7@IOM^J:YJT2D6MU<!83_ '@HY-&Z=P)M'FD?X@:[&TCF
M-(HMJD\#CL*W-7U>UT73Y+R\?;&@Z#JQ[ #UK T7_DHNO_\ 7&'^50W<8\2?
M$!;.;YK+28Q(R=FE;IGZ536HA(8?$GBI?/DN6T;3WYCBC&9F7L2>U2_\( @&
MZ/6]667^_P"?G]*ZX#%+2YNPSB9;[7_!Y$FI2?VKI0.&G5<2Q#U([BNPL[N&
M^M8KFVD62&50RLO0BGRQI+&T<BAD8892."*Y+PH#HGB/4_#^XFW3%S:@G[JM
MU%&Z Z/69YK71[R>W($T<3.A(SR!7D:_$_Q$ ,RVY^L0KV6>)9X)(GY5U*GZ
M&OGC5+"33-4N;.4$-#(5Y].WZ5K049:,B3:/1?!7CO4]<U];+46@\MXV*[$P
M<BO1<"OG33+^;2M2@O;<_O(7##W]17O&@:_9^(;!;FS<$X_>1G[R'T-*M#E=
MT.+N:!MXS*)=B^8. V.:DHI&( ))  ZDUB4<M\175?#15B-S3*%%>6'I]:ZK
MQQX@35KY+6U?=;6Q/S#HS=S6+H6GMJFLVUJHR&<%_91UKT**Y*?O'//66A[)
MIP*Z;:JW40J#^5<[X[N[R"+2X;*[EM3<W:Q.\?7!KJE 4  8 X%<EX]_UF@_
M]A!*X8ZR-WL._P"$0U/_ *&K4_R%'_"(:G_T-6I?D*ZREHYY#L<YI'@ZTTR^
M^W3SSWU]VGN&R5^@[58\7W4UCX5U"XM9&CFCCRKKU'(K:K \<?\ (EZI_P!<
M?ZBDG>2 RK#PSJEYIUO<MXHU%3-&KD #C(S4[>$=2523XJU+ &>@K>T/_D!6
M'_7NG_H(J^>E-R=Q6.'T'PYIFN;-2N=3O-6$,A54N3@(P/=:[.=0MM(!P A_
ME7'O_P 4EXT#_=TO6&P?2.;_ .O783_\>TO^X?Y42W XKPEILVJ>!(8(;Z>R
M87$C>9#U^\>*N_\ "&7_ /T-&I_I3_AS_P BC#_UVD_]"KJJ')INPSG=*\-7
M>GZ@EQ+KU]=HH(,4N-IKHJ*,U+=P.2UXBW\?^'YY/]6ZR1 GIN(XKK16%XMT
M1];TC;;-LO8&$UL_HX[?C4?AGQ/#K$1M[G_1]2@^6>W?ALCN!W!IO5*P'144
MVEI ,E_U,G^Z:Y3X>DKX.8C@B>8C_OHUU<I_<O\ [IKE/A]_R)S?]=IO_0C5
M+X6)F7X:TS5O$6EF^D\1W\!:9UV)@@8-:W_"'ZG_ -#5J7Y"E^''_(J_]O,O
M_H5=93<FGH%CD'\"&\(35=<U&]@!YA9MJM]<5U%K:0V5M';VT:QPQC:J*, "
MIZ0U#;8SDM%_Y*+K_P#UQB_E3?#Y\CQ]XB@DXDE\N5,]UQBG:+_R477_ /KC
M#_*CQ78W5CJ-MXBTR,R36R[+F%>LL7^(K2^MNXCK12UFZ-K5EKEDMS83+(I^
M\N?F0^A':M'-9[#$-<E"?M'Q4F:/D6]@%D(]2<BM7Q%XDM- M-TA\RY?B&W3
MEW;MQ57P?H]S8V]Q?ZESJ-^_FS#^X.R_A5+34#HR,UYY\2_"DEX@UBQC+31K
MMG11RRCHWX5Z)2$ YR*49.+NA-7/FI%+N%4$DG@5W_A'Q OABV:W:U65)&W.
MZG#Y_K78'P%HIU2>]^SG=,N#&#A5/=AZ&LB_^'DRL6T^Y5E[)+P?SKI]K">D
MC"HJB^$L:C\1;>&%#96SRNQ.Y9/EV_XURVK^,=3U=&B9U@@/!CBXS]33-5\-
M:I8-&LMLS%R<>7\W\JDT_P $ZQ?E28!!&?XI6QQ]*TA&E%<PE*<E9F"JEF"J
M"23@ =37I_@CPT=)M6N[M<7<PQM/_+-?3ZU8T#P99:*PFD/VBZ'\;#A?]T5T
M@%95J_/[L=C6$+:L*R-?T(:VUB?.,7V2X6?IG=CM6Q25S+0T 4M%% !6?KFF
M#6=&NK#S#%YZ;=^,XK0HH KV-M]CL8+;=N\F-4W8ZX&,U/12T 9>OZ+#KVDR
MV4QV;L,D@'*,.A%6K>V>+3H[:64RR+$$:0C[QQC-6:,4 <38>#==TRW^SV/B
M/RH Q94%N#C)SZU8_P"$=\4?]#1_Y+#_ !KKL457.Q6.1_X1WQ1_T-/_ )+#
M_&KNDZ/KEG?++?Z[]K@ (,7DA<GL<UT5)BCF;"PF,BL;6_">G:VZS3(\5TOW
M;B$[7'X]ZVJ6I6@SD!X6U^#Y+;Q5<>6.@EA#$?C2_P#".>)O^AI;_P !Q_C7
M6XHQ5<S%8H:7:7=KIJP7]X;N?D--MVY_"J_A_0QH6CFQ\XS9D=]^,?>.:U\4
M8J;C,KPYHHT#2_L8F\[]Z\FXC'WCG%:U)BEH *0TM)0!D66A_9/$=_JGG%OM
MB(OE[?N[?>M8KFEI:'J!S.H^"+*ZNVN[&>?3;MCDR6S8#'W7I5;_ (1;Q _R
M2>*KCR^AVQ -CZUU])BGS,# T?P=I^DW!NCYMW>GK<7#;F_#TK? HI:&V]P"
MBBBD E%%% !1110 4M%%) %%%%, HHHH **** "BBB@ HHHH **** "BBB@
BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
